Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP705 in Adult Patients With Basal Cell Carcinoma
NCT04669808Phase 2Completed
- Sponsor
- Sirnaomics
- Start
- Dec 2020
- Primary completion
- Feb 2023
- Modality
- Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, open-label trial of sirna-tgf-b1 + sirna-cox-2 in basal cell carcinoma (BCC) (7 cohorts), sponsored by Sirnaomics. Primary endpoint: Proportion of Participants With Histological Clearance of Treated Basal Cell Carcinoma Lesion at 6 weeks. Started Dec 2020; status: completed.
02
Drugs
sirna-tgf-b1 + sirna-cox-2
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT04669808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669808.